Literature DB >> 10803480

Testosterone therapy in men: clinical and pharmacological perspectives.

A Gambineri1, R Pasquali.   

Abstract

There is increasing evidence that androgen therapy in men may be effectively applied in several conditions to improve well being and health. Classical indications for androgen therapy in males are represented by primary or secondary hypogonadism, delayed puberty, aplastic anemia and that secondary to chronic renal failure, protein wasting diseases such as trauma, burns, tumors and infectious diseases. Androgen innovating applications in men are represented by aging and visceral obesity associated with the metabolic syndrome. In addition, it is clear that appropriate testosterone treatment can be adequately used in male contraception, provided spermatogenesis is abolished and tolerability is adequate. Due to unphysiological hormone levels achieved by currently available testosterone preparations, new delivery systems have been produced to achieve more physiological and sustained hormone levels and improve tolerability and action at the levels of target tissues. Some of them are now available in several countries and new formulas are under development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10803480     DOI: 10.1007/BF03343707

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  130 in total

1.  THE METABOLISM OF 4-14C-17-ALPHA-METHYLTESTOSTERONE.

Authors:  A SEGALOFF; R B GABBARD; B T CARRIERE; E L RONGONE
Journal:  Steroids       Date:  1965       Impact factor: 2.668

2.  Sexual differentiation; Factor determining forms of obesity.

Authors:  J VAGUE
Journal:  Presse Med       Date:  1947-05-24       Impact factor: 1.228

3.  Contrasting effects of testosterone and stanozolol on serum lipoprotein levels.

Authors:  P D Thompson; E M Cullinane; S P Sady; C Chenevert; A L Saritelli; M A Sady; P N Herbert
Journal:  JAMA       Date:  1989-02-24       Impact factor: 56.272

Review 4.  Androgens in men--uses and abuses.

Authors:  C J Bagatell; W J Bremner
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

5.  The effect of anabolic steroids on lean body mass: the dose response curve.

Authors:  G B Forbes
Journal:  Metabolism       Date:  1985-06       Impact factor: 8.694

6.  Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.

Authors:  H M Behre; S Baus; S Kliesch; C Keck; M Simoni; E Nieschlag
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

7.  The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity.

Authors:  J M Zmuda; M C Fahrenbach; B T Younkin; L L Bausserman; R B Terry; D H Catlin; P D Thompson
Journal:  Metabolism       Date:  1993-04       Impact factor: 8.694

8.  Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.

Authors:  C A Stuenkel; R E Dudley; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1991-05       Impact factor: 5.958

Review 9.  The use and misuse of androgens.

Authors:  J D Wilson; J E Griffin
Journal:  Metabolism       Date:  1980-12       Impact factor: 8.694

10.  Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive.

Authors:  W J Bremner; C J Bagatell; R A Steiner
Journal:  J Clin Endocrinol Metab       Date:  1991-09       Impact factor: 5.958

View more
  7 in total

1.  Endocrine and metabolic alterations in obstructive sleep apnea syndrome.

Authors:  F Lanfranco; L Gianotti; M Maccario
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

2.  Short-term modification of sex hormones is associated with changes in ghrelin circulating levels in healthy normal-weight men.

Authors:  A Gambineri; U Pagotto; R De Lasio; M C Meriggiola; A Costantino; L Patton; C Pelusi; G Pelusi; R Pasquali
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

3.  Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  P Härle; G Pongratz; C Weidler; R Büttner; J Schölmerich; R H Straub
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

4.  Testosterone levels in obese male patients with obstructive sleep apnea syndrome: relation to oxygen desaturation, body weight, fat distribution and the metabolic parameters.

Authors:  A Gambineri; C Pelusi; R Pasquali
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

5.  Gender Differences in the Context of Obstructive Sleep Apnea and Metabolic Diseases.

Authors:  Fátima O Martins; Sílvia V Conde
Journal:  Front Physiol       Date:  2021-12-14       Impact factor: 4.566

Review 6.  Obstructive Sleep Apnea and Testosterone Deficiency.

Authors:  Sung Dong Kim; Kyu Sup Cho
Journal:  World J Mens Health       Date:  2018-05-16       Impact factor: 5.400

7.  [Evaluation of testosterone serum levels in patients with obstructive sleep apnea syndrome].

Authors:  Fernando Drimel Molina; Marcela Suman; Thiago Bittencourt Ottoni de Carvalho; Vânia Belintani Piatto; Sebastião Roberto Taboga; José Victor Maniglia; Waldir Antônio Tognola
Journal:  Braz J Otorhinolaryngol       Date:  2011 Jan-Feb
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.